The global primary cell culture market has been witnessing significant growth due to the growing adoption of cell-based research methods across various industries such as biotechnology, pharmaceutical, and cosmetics. Primary cell cultures are human or animal cells that are cultured or grown under controlled conditions in laboratories. They provide researchers with vital information for disease modeling, drug discovery and development, and toxicity studies. Advantages of primary cell cultures include their ability to retain many characteristics of the native cells and exhibit behaviors more similar to in vivo conditions. The growing demand for personalized medicine, regenerative therapies, and cell-based research has fueled the need for primary cell cultures.
The Global Primary Cell Culture Market Growth is estimated to be valued at US$ 5.99 BN in 2024 and is expected to exhibit a CAGR of 10.% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the global primary cell culture market are Merck KGaA, Thermo Fisher Scientific, Inc., Danaher, Lonza, PromoCell GmbH, Corning Incorporated, FUJIFILM Irvine Scientific, Inc., Mattek, Axol Bioscience Ltd., ATCC, QIAGEN and HiMedia Laboratories. These players are focusing on new product launches and expansions to strengthen their market presence.
The key opportunities in the primary cell culture market include increasing R&D investments in cell-based research by biopharmaceutical companies and growing stem cell research. Emerging economies are also expected to offer lucrative growth opportunities for players due to rising healthcare expenditures and improving research infrastructure in countries such as China, India, and Brazil.
The growing demand for personalized medicines and regenerative therapies is driving global expansions of major players. For instance, Thermo Fisher Scientific expanded its facility in Alabama in 2021 to support increasing cell culture production demands. Corning also expanded its bioprocess products portfolio with the acquisition of cell culture media company Cultilab in 2021 to better serve the global cell culture market.
Market drivers
The primary driver fueling the growth of the primary cell culture market is the increasing investments in cell-based research by biopharmaceutical and medical technology companies. According to estimates, global spending on R&D by biopharmaceutical companies increased from $71 billion in 2006 to $151 billion in 2016 and is expected to witness further rise in the coming years. Additionally, improving regulatory guidelines regarding the adoption of alternative methods over animal testing is augmenting the demand for cell-based assays using primary cell cultures.
PEST Analysis
Political: The global primary cell culture market is influenced by various governmental regulations related to healthcare, research and development spending. Stringent laws for drug development and approval processes impact the growth of this market.
Economic: Rising per capita healthcare expenditure along with growing biomedical and pharmaceutical research and development activities is fueling the demand for primary cell culture worldwide. Government funding for life science research also supports market growth.
Social: Increasing prevalence of chronic diseases like cancer is leading to greater research emphasis on developing novel drugs and therapies. Growing awareness about personalized medicine and cell-based therapies drives market expansion.
Technological: Advancements in cell isolation and culture techniques along with development of serum-free and chemically defined media are enhancing cell viability and functionality. Automation and digitalization trends ensure high productivity and reproducibility.
North America holds the largest share of the primary cell culture market due to heavy investments in biomedical R&D, strong presence of key industry players, and high adoption of advanced technologies. The United States accounts for the major share due to robust research funding and rise in pharmaceutical outsourcing.
The Asia Pacific region is poised to grow at the fastest rate during the forecast period. Factors such as emerging economies, expanding biopharmaceutical industry, increasing healthcare spending, and rising pharmaceutical outsourcing to China, India and Singapore support market growth. Rising incidence of chronic diseases with unmet clinical needs also stimulates research activities and primary cell culture demand in the region.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it